Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Bayer ( (DE:BAYN) ) is now available.
Bayer disclosed that Management Board member Dr. Judith Hartmann purchased Bayer shares on March 5, 2026 via the Xetra trading platform, in line with the board’s commitment to buy company stock. The series of transactions, executed at prices around €37.36 per share and totaling approximately €485,615, underscores continued insider alignment with shareholder interests and provides investors with additional transparency on executive dealings in Bayer equity.
The most recent analyst rating on (DE:BAYN) stock is a Buy with a EUR48.00 price target. To see the full list of analyst forecasts on Bayer stock, see the DE:BAYN Stock Forecast page.
More about Bayer
Bayer Aktiengesellschaft is a Germany-based life sciences company with core businesses in health care and agriculture. Its primary products range from pharmaceuticals and consumer health items to crop science solutions, and its shares are listed on several regulated markets across major German stock exchanges.
YTD Price Performance: -1.68%
Average Trading Volume: 3,861,126
Technical Sentiment Signal: Sell
Current Market Cap: €35.75B
For detailed information about BAYN stock, go to TipRanks’ Stock Analysis page.